Changes in Hong Kong stocks | Tongyuankang Pharmaceutical-B (02410) rose more than 10%, major shareholders increased their holdings to boost market confidence. Previously, core products were successfully approved

The Zhitong Finance App learned that Tongyuankang Pharmaceutical-B (02410) fluctuated higher this morning. As of press release, it had risen 10.1% to HK$3.38, with a turnover of HK$3.89.48 million.

According to the news, according to the latest data from the Hong Kong Stock Exchange, Wu Yusheng, the chairman and CEO of the company, increased his holdings by 170,000 shares by HK$2,7036 each on September 11, involving about HK$459,600. After the increase in holdings, his shareholding ratio rose to 32.69%. Earlier, Wu Yusheng had purchased 635,000 H shares on the open market from September 8 to 10, involving an investment of about HK$2.09 million, and stated that the subsequent increase in holdings is expected to be no more than HK$3 million.

Furthermore, at the end of August this year, Tongyuankang Pharmaceutical revealed that its core product was successfully approved. The next-generation EGFR-TKI innovative drug deuterosenitinib mesylate tablets (TY-9591 tablets) independently developed by the company has obtained NMPA approval and is conditionally marketed domestically. The indications are first-line treatment for adult patients with EGFR 19DEL or L858R replacement mutations and CNS metastases.